GET DAILY SIGNALSWhy Is Rhythm Pharmaceuticals (RYTM) Stock Down -7.97% Today?
Key Takeaways
- Shares fell about 7.97% in intraday trading, dropping from a prior close of $93.44 to roughly $85.99.
- The decline came despite a third-quarter earnings beat, with revenue of $92.1 million and a smaller-than-expected loss of $0.61 per share.
- The primary drag was an amended LG Chem licensing deal carrying $350 million in fixed payments, alongside a new $750 million term-loan facility.
- Investors also weighed elevated 2026 operating-expense guidance of $360 million to $380 million and a longer path to profitability.
- The move followed a multi-day run-up, suggesting a "sell-the-news" and profit-taking dynamic.
- Traders are watching the post-earnings reaction, cash-burn trajectory, and the acquired hypothalamic obesity (HO) launch momentum.
- For more detail, explore Price Targets, Earnings, and Forecast pages dedicated to RYTM.
- To see which automated strategies are currently outperforming, browse the Trending AI Robots section.
Opening Summary
Rhythm Pharmaceuticals, Inc. (RYTM), a Boston-based commercial-stage biopharmaceutical company developing therapies for rare genetic and neuroendocrine diseases of obesity, saw its shares fall sharply on Monday despite posting stronger-than-expected third-quarter results. The stock declined approximately 7.97% in intraday trading to around $85.99, down from a previous close of $93.44. The selloff underscored investor unease over a newly amended licensing agreement, a sizable new debt facility, and elevated spending plans—even as the company's lead therapy, IMCIVREE (setmelanotide), continued to gain commercial traction.
Earnings Beat Met With a "Sell-the-News" Reaction
At first glance, the quarter looked solid. RYTM reported third-quarter net product revenue of $92.1 million, up roughly 79% year over year and ahead of the consensus estimate near $85.4 million. Net loss per share narrowed to $0.61, better than the $0.71 loss analysts had projected. Global revenue rose 29% sequentially, driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity, while the number of patients on reimbursed therapy grew 20% quarter over quarter.
Yet the share-price response was decidedly negative. With RYTM having climbed in the prior week, the earnings release triggered a classic "sell-the-news" episode: investors appeared to focus less on the beat and more on the company's escalating cash commitments and spending profile as it scales commercialization.
LG Chem Amendment and $750 Million Financing
The most consequential announcement was the amendment to RYTM's exclusive license agreement with LG Chem covering the next-generation MC4R agonist bivamelagon. The revised terms lower future royalties on MC4R portfolio sales to 1%, but require $350 million in fixed payments over four years—including $70 million due within 15 business days—plus a new $200 million sales milestone.
To fund these obligations and pipeline development, the company also entered a five-year term-loan facility led by KKR's HealthCare Royalty in partnership with Blackstone Life Sciences, providing up to $750 million of capital. While management framed the deal as "buying down" future royalties to improve long-term economics, the market reacted to the near-term fixed cash outflows and added leverage, which increase financial risk if commercialization or development timelines slip.
Elevated Operating-Expense Guidance
Adding to the cautious tone, RYTM guided to 2026 non-GAAP operating expenses of $360 million to $380 million, split between R&D spending of $165 million to $175 million and SG&A of $195 million to $205 million. Combined with a still-unprofitable bottom line, the guidance reinforced that the company's path to profitability will require sustained launch growth and disciplined spending—a profile that prompted some investors to lock in gains.
Market Context and Trading Activity
The decline was accompanied by notably heavier trading, with volume running well above the stock's 20-day average of roughly 670,000 shares. The move diverged from the broader tape, indicating company-specific catalysts rather than sector-wide pressure drove the action. From a technical standpoint, the pullback pushed RYTM back below its 50-day and 200-day moving averages, both of which sit near the $97 level, and toward the lower end of its recent $86-to-$93 trading range.
What Comes Next for RYTM
Looking ahead, investors will monitor whether the U.S. acquired HO launch sustains its momentum and how quickly the newly launched Japanese market—positioned by management as a potential second-largest market—begins contributing. Key watch items include the pace of patient start forms, reimbursement approval rates, and updates on the planned Phase 3 bivamelagon programs in acquired HO and Prader-Willi syndrome. Risks include the fixed cash obligations under the amended LG Chem agreement, rising R&D and SG&A spending, and the possibility that launch growth decelerates as the indication matures.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of these automated strategies covering thousands of tickers, with bots varying by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this section, giving traders a focused view of what is working right now. Explore Trending AI Robots to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
RYTM in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 07, 2026
RYTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 30 cases where RYTM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RYTM's RSI Oscillator exited the oversold zone, 14 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RYTM as a result. In 64 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for RYTM just turned positive on October 20, 2026. Looking at past instances where RYTM's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
Following a +3.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in 236 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for RYTM moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for RYTM entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 20 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (62.472) is slightly higher than the industry average of (3.104). P/E Ratio (-29.949) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (27.548) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of peptide therapeutics for metabolic diseases
Industry Biotechnology
Advertisement